C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/10 (2006.01) A61K 45/00 (2006.01) C12N 15/10 (2006.01) C12Q 1/00 (2006.01) C12Q 1/68 (2006.01) C12N 15/09 (2006.01) C12N 5/06 (2006.01)
Patent
CA 2630432
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
La présente invention concerne des animaux transgéniques, ainsi que des compositions et des procédés concernant la caractérisation de la fonction génique. Spécifiquement, la présente invention concerne une souris transgénique comprenant des dissociations des gènes PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 ou PRO346. Ces études et ces caractérisations in vivo permettent d'identifier et de découvrir des agents thérapeutiques et/ou des traitements de valeur utiles dans la prévention, l'amélioration ou la correction de maladies ou de dysfonctions associées à des dissociations de gènes, par exemple les troubles neurologiques ; les troubles cardiovasculaires, endothéliaux ou angiogènes ; les anomalies oculaires ; les troubles immunologiques ; les troubles oncologiques ; les anomalies ou les troubles du métabolisme osseux ; les troubles du métabolisme des lipides ; ou les anomalies développementales.
Combs Katherin E.
Desauvage Frederic
Fan Liangfen
Filvaroff Ellen
Horner Allison Anne Byers
Genentech Inc.
Lexicon Pharmaceuticals Inc.
Smart & Biggar
LandOfFree
Novel gene disruptions, compositions and methods relating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel gene disruptions, compositions and methods relating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel gene disruptions, compositions and methods relating... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1945549